JP2015509960A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509960A5
JP2015509960A5 JP2014560085A JP2014560085A JP2015509960A5 JP 2015509960 A5 JP2015509960 A5 JP 2015509960A5 JP 2014560085 A JP2014560085 A JP 2014560085A JP 2014560085 A JP2014560085 A JP 2014560085A JP 2015509960 A5 JP2015509960 A5 JP 2015509960A5
Authority
JP
Japan
Prior art keywords
seq
antibody
pharmaceutical composition
antigen
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014560085A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015509960A (ja
JP6193275B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/028602 external-priority patent/WO2013130959A1/en
Publication of JP2015509960A publication Critical patent/JP2015509960A/ja
Publication of JP2015509960A5 publication Critical patent/JP2015509960A5/ja
Application granted granted Critical
Publication of JP6193275B2 publication Critical patent/JP6193275B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014560085A 2012-03-02 2013-03-01 B細胞媒介炎症性疾患を治療するための方法 Active JP6193275B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261606049P 2012-03-02 2012-03-02
US61/606,049 2012-03-02
PCT/US2013/028602 WO2013130959A1 (en) 2012-03-02 2013-03-01 Methods for the treatment of b cell-mediated inflammatory diseases

Publications (3)

Publication Number Publication Date
JP2015509960A JP2015509960A (ja) 2015-04-02
JP2015509960A5 true JP2015509960A5 (enExample) 2016-04-21
JP6193275B2 JP6193275B2 (ja) 2017-09-06

Family

ID=47844534

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014560085A Active JP6193275B2 (ja) 2012-03-02 2013-03-01 B細胞媒介炎症性疾患を治療するための方法

Country Status (10)

Country Link
US (1) US9890213B2 (enExample)
EP (1) EP2820045B1 (enExample)
JP (1) JP6193275B2 (enExample)
KR (1) KR102090969B1 (enExample)
CN (1) CN104520323B (enExample)
AU (1) AU2013225812B2 (enExample)
CA (1) CA2865928C (enExample)
IN (1) IN2014DN08199A (enExample)
NZ (1) NZ629828A (enExample)
WO (1) WO2013130959A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2427212T3 (pl) 2009-05-08 2018-02-28 Vaccinex, Inc. Przeciwciała anty cd-100 i sposoby ich zastosowania
EP2611832B1 (en) 2010-09-02 2017-11-29 Vaccinex, Inc. Anti-cxcl13 antibodies and methods of using the same
EA029023B1 (ru) 2011-10-11 2018-01-31 Вэксинекс, Инк. Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
JP6363623B2 (ja) 2013-01-31 2018-07-25 ヴァクシネックス, インコーポレイテッド 免疫グロブリンaのレベルを増大するための方法
SG10201902380SA (en) 2013-06-25 2019-04-29 Vaccinex Inc Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
EP4059516A1 (en) 2016-04-22 2022-09-21 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
SG11201900595YA (en) 2016-08-02 2019-02-27 Vaccinex Inc Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
PL3328887T3 (pl) * 2016-09-19 2021-12-27 I-Mab Biopharma (Hangzhou) Co., Ltd. Przeciwciała anty-gm-csf i ich zastosowania
EP3801558A4 (en) * 2018-05-31 2022-03-09 Glycom A/S HMOS BLEND FOR THE TREATMENT OF AUTOIMMUNE DISEASES
MX2021002605A (es) * 2018-09-18 2021-07-21 I Mab Biopharma Us Ltd Anticuerpos anti-cxcl13 para el tratamiento de enfermedades autoinmunes y cancer.

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
JP3583420B2 (ja) 1990-10-05 2004-11-04 メダレツクス・インコーポレーテツド 二特異的試薬を用いた標的免疫化
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
IE921342A1 (en) 1991-04-26 1992-11-04 Surface Active Ltd Novel antibodies, and methods for their use
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5633149A (en) 1994-12-07 1997-05-27 Incyte Pharmaceuticals, Inc. Polynucleotide encoding novel chemokine expressed in inflamed adenoid
US6692920B1 (en) 1994-12-07 2004-02-17 Incyte Corporation Antibodies to a chemokine expressed in inflamed adenoid
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
KR19990022283A (ko) 1995-06-05 1999-03-25 벤슨 로버트 에이치. 인체 케모킨 베타-11 및 인체 케모킨 알파-1
AU4243097A (en) 1996-09-10 1998-04-02 Schering Corporation Mammalian chemokines, related reagents
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
US6110695A (en) 1997-12-02 2000-08-29 The Regents Of The University Of California Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
US6723538B2 (en) 1999-03-11 2004-04-20 Micromet Ag Bispecific antibody and chemokine receptor constructs
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
JP2003530325A (ja) 2000-03-31 2003-10-14 イーペーエフ ファルマシューティカルス ゲゼルシャフト ミット ベシュレンクテル ハフツング 好ましくは特異的ケモカインレセプター分析、及びケモカインレセプター/リガンド相互作用の助けによる、腫瘍及び炎症細胞の細胞表面プロテオームの調査、並びに腫瘍疾患及び炎症性疾患の治療のための診断薬及び薬剤
GB2361003A (en) 2000-04-07 2001-10-10 Astrazeneca Ab Novel compounds
US7052676B2 (en) 2000-09-26 2006-05-30 The Regents Of The University Of Michigan Methods for inhibition of HIV replication using a small molecule inhibitor
MXPA03004913A (es) 2000-12-01 2003-09-05 Schering Corp Usos de genes de mamifero y reactivos relacionados.
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US6818406B2 (en) 2001-03-23 2004-11-16 Mayo Foundation For Medical Education And Research Rheumatoid arthritis markers
US7442512B2 (en) 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7413866B2 (en) 2001-11-30 2008-08-19 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP4524181B2 (ja) 2002-05-30 2010-08-11 マクロジェニクス,インコーポレーテッド Cd16a結合タンパク質および免疫障害治療のための使用
EP1576137A4 (en) 2002-10-29 2010-06-30 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
WO2004045526A2 (en) 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
US7964194B2 (en) 2002-11-15 2011-06-21 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation
JP2011516026A (ja) 2002-11-26 2011-05-26 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
EP1613657A2 (en) 2003-03-28 2006-01-11 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
JP2007532656A (ja) 2004-04-12 2007-11-15 アメリカ合衆国 アデノウイルスベクターを用いて免疫応答を誘導するための方法
CA2501422C (en) 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
CA2544692C (en) 2004-07-09 2014-04-01 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
EA200701211A1 (ru) 2004-12-31 2007-12-28 Дженентек, Инк. Полипептиды, которые связываются с br3, и их применение
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
WO2007064911A1 (en) 2005-12-02 2007-06-07 Biogen Idec Inc. Anti-mouse cd20 antibodies and uses thereof
GB0607774D0 (en) * 2006-04-20 2006-05-31 Renovo Group Plc Medicaments
RU2449808C2 (ru) 2006-04-21 2012-05-10 Сентокор, Инк. Антагонисты cxcl13 и их применение для лечения воспалительных заболеваний
US20080227704A1 (en) 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
US20080199481A1 (en) * 2007-02-21 2008-08-21 Astrazeneca Ab Compounds
WO2008121940A1 (en) * 2007-03-30 2008-10-09 Centocor, Inc. Cxcl13 antagonists and their use for the treatment of inflammatory diseases
US20110300167A1 (en) * 2008-11-04 2011-12-08 Mcmurry Thomas J Cxcr5 receptor compounds
EP2611832B1 (en) * 2010-09-02 2017-11-29 Vaccinex, Inc. Anti-cxcl13 antibodies and methods of using the same
CN104114187A (zh) 2011-12-28 2014-10-22 诺沃姆德治疗公司 去糖基化的人类抗体、其融合蛋白质及用途
JP6363623B2 (ja) 2013-01-31 2018-07-25 ヴァクシネックス, インコーポレイテッド 免疫グロブリンaのレベルを増大するための方法
CA2902442A1 (en) 2013-03-08 2014-09-12 Vaccinex, Inc. Anti-cxcl13 antibodies and associated epitope sequences

Similar Documents

Publication Publication Date Title
JP2013198490A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
JP2009225799A5 (enExample)
JP2014511179A5 (enExample)
JP2015163068A5 (enExample)
JP2018512138A5 (enExample)
HRP20150443T1 (hr) Djelotvorne tvari koje se vežu za notch i njihovi antagonisti te postupci njihove uporabe
JP2014205674A5 (enExample)
HRP20200767T1 (hr) Humanizirana anti-humana cd19 protutijela i postupci uporabe
JP2017535257A5 (enExample)
HRP20220405T1 (hr) Protutijela protiv ngf i njihova upotreba
JP2019516394A5 (enExample)
JP2016505556A5 (enExample)
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
JP2009521496A5 (enExample)
HRP20201022T1 (hr) Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba
JP2015504421A5 (enExample)
ME02678B (me) Antitijela na ox-40 i postupci njihove primjene
HRP20221088T1 (hr) Protutijela i postupci uporabe
JP2017514461A5 (enExample)
JP2014158469A5 (enExample)
HRP20221471T1 (hr) Protutijela anti-fgfr3 i postupci za njihovu uporabu
JP2014522850A5 (enExample)
JP2013506428A5 (enExample)
HRP20250602T1 (hr) Antitijela koja se vežu na sortilin i inhibiraju vezanje progranulina